Silence Therapeutics PLC Sponsored ADR SLN 深 沪
等待开盘 04-02 09:30:00 美东时间
5.40
+0.130
+2.47%
华盛通- 最 高5.825
- 今 开5.29
- 成交量 14.31万股
- 最 低 5.27
- 昨 收 5.27
- 总市值 2.55亿
- 52周最高 7.91
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 2.445
- 委 比 -75.34%
- 总股本 4723.39万
- 历史最高 35.00
- 量 比 0.73
- 振 幅 10.53%
- 历史最低 1.97
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Urgent.ly Shares Are Trading Higher By Around 159%; Here Are 20 Stocks Moving Premarket
Urgent.ly shares surged in pre-market trading after agreement to be acquired by Agero for $5.50 per share. Also reported better-than-expected Q4 results.
03-16 17:39
Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.
Silence Therapeutics shares are trading lower after the company reported worse-...
03-06 00:12
Silence Therapeutics Q4 Earnings Assessment
Silence Therapeutics (NASDAQ:SLN) released its Q4 earnings on Thursday, March 5...
03-05 20:58
Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from
03-05 20:57
Silence Therapeutics President And CEO Craig Tooman Steps Down; Chairman Iain Ross Named Interim Leader
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the
2025-12-15 21:17
Silence Therapeutics Q3 EPS $(0.15) Beats $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 40 percent increase over losses of $(0.25) per share from
2025-11-06 20:39
Silence Therapeutics Completes Patient Enrollment in Phase 2 Study of Divesiran
Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO Phase 2 study of
2025-10-23 19:34
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
2025-09-17 10:15
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
2025-09-16 18:49
Michael Davidson Resigns from Silence Therapeutics Board
The latest announcement is out from Silence Therapeutics ( ($SLN) ). On August ...
2025-08-14 18:57
